TAK-861 demonstrated statistically significant and clinical improvement in patients suffering from type 1 narcolepsy, the company said in a
The drug is among several candidates Takeda is counting on to buffer a drop in sales when its blockbuster drug Entyvio for treating ulcerative colitis loses patent protection around ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.